AML/CML Flashcards
Big 4 of AML
t(8;21), inv(16), t(15;17), abnormal 11q23
t(8;21) -> gene
AML1-ETO or RUNX1-RUNX1T1 -> translocation
inv(16) -> gene
CBFB-MYH11 -> translocation
t(15;17) -> gene
PML-RARA -> translocation
abnormal 11q23 -> gene
MLL-partner -> translocation
DBA gene
RPS19, RPL5 -> disorder
t-AML from topo II + latency
11q23, latency 1-2yrs
t-AML from alkylators/radiation + latency
-5, -7, del(5q), del(7q), latency 5-7
AMKL mutation
GATA1 with DS
AMKL immunophenotype
CD42+, CD61+, absent MPO
“RAM” immunophenotype
bright CD56, dim/neg CD45, dim/neg CD 38 and neg HLA-DR
Gemtuzumab ozogamicin target
CD33
HR APL
WBC > 10K (add idarubicin)
CML blast percentage for chronic phase
<10% in bone marrow or serum
CML blast percentage for accelerated phase
10-19% in the bone marrow or serum